A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat
Tóm tắt
Từ khóa
Tài liệu tham khảo
Schrijvers BF, De Vriese AS, Flyvbjerg A. From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokine. Endocr Rev2004; 25: 971–1010
De Vriese AS, Tilton RG, Elger M et al. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol2001; 12: 993–1000
Flyvbjerg A, Dagnæs-Hansen F, De Vriese AS et al. Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes2002; 51: 3090–3094
Schrijvers BF, De Vriese AS, Tilton RG et al. Inhibition of vascular endothelial growth factor (VEGF) does not affect early renal changes in a rat model of lean type 2 diabetes. Horm Metab Res2005; 37: 21–25
Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int2004; 65: 2003–2017
Foster RR, Hole R, Anderson K et al. Functional evidence that vascular endothelial growth factor may act as an autocrine factor on human podocytes. Am J Physiol2003; 284: F1263–F1273
Gerber HP, Dixit V, Ferrara N. Vascular endothelial growth factor induces expression of the anti-apoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem1998; 273: 13313–13316
Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest1999; 103: 159–165
Peterson RG, Shaw WN, Neel M-A, Little LA, Eichberg J. Zucker diabetic fatty rat as a model for non-insulin-dependent diabetes mellitus. ILAR News1990; 32: 16–19
Corsetti JP, Sparks JD, Peterson RG, Smith RL, Sparks CE. Effect of dietary fat on the development of non-insulin dependent diabetes mellitus in obese Zucker diabetic fatty male and female rats. Atherosclerosis2000; 148: 231–241
Hoshi S, Shu Y, Yoshida F et al. Podocyte injury promotes progressive nephropathy in Zucker diabetic fatty rats. Lab Invest2002; 82: 25–35
Schäfer S, Linz W, Bube A et al. Vasopeptidase inhibition prevents nephropathy in Zucker diabetic fatty rats. Cardiovasc Res2003; 60: 447–454
Slee EA, Adrain C, Martin SJ. Executioner caspase-3, -6, and -7 perform distinct, non-redundant roles during the demolition phase of apoptosis. J Biol Chem2001; 276: 7320–7326
Janssen SWJ, Martens GJ, Sweep CG, Ross HA, Hermus AR. In Zucker diabetic fatty rats plasma leptin levels are correlated with plasma insulin levels rather than with body weight. Horm Metab Res1999; 31: 610–615
Nyengaard JR, Rasch R. The impact of experimental diabetes mellitus in rats on glomerular capillary number and sizes. Diabetologia1993; 36: 189–194
Tilton RG, Kawamura T, Chang KC et al. Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor. J Clin Invest1997; 99: 2192–2202
Satchell SC, Mathieson PW. Angiopoietins: microvascular modulators with potential roles in glomerular pathophysiology. J Nephrol2003; 16: 168–178
Lobov IB, Brooks PC, Lang RA. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA2002; 99: 11205–11210
Yamamoto Y, Maeshima Y, Kitayama H et al. Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy. Diabetes2004; 53: 1831–1840